Integrated BioPharma Inc (INBP)
OTHER OTC:INBP
INBP Stock Chart & Stats
$0.34
$0.02(5.88%)
At close: 4:00 PM EST
$0.34
$0.02(5.88%)
Day’s Range― - ―
52-Week Range$0.25 - $0.42
Previous CloseN/A
Volume200.00
Average Volume (3M)15.15K
Market Cap
$8.67M
Enterprise Value$4.03M
Total Cash (Recent Filing)$5.31M
Total Debt (Recent Filing)$649.00K
Price to Earnings (P/E)―
Beta-0.02
Next Earnings
May 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding31,059,610
10 Day Avg. Volume31,065
30 Day Avg. Volume15,153
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.53
Price to Sales (P/S)0.20
P/FCF Ratio5.77
Enterprise Value/Market Cap0.46
Enterprise Value/Revenue0.08
Enterprise Value/Gross Profit0.99
Enterprise Value/Ebitda2.21
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetExtremely low leverage gives durable financial flexibility: the company can fund working capital, tolerate revenue volatility, and pursue selective investments without relying on external debt. This reduces bankruptcy risk and supports long-term contract-manufacturing credibility with clients.
Positive And Growing Free Cash FlowConsistent positive operating and free cash flow provides a sustainable internal funding source for capex, quality control, and working-capital needs. Growing FCF improves resilience against revenue dips and lessens the need for dilutive financing over the medium term.
Diversified Manufacturing + Branded Sales ModelA dual model—making its own branded products while offering contract manufacturing—creates diversified revenue streams and cross-selling opportunities. Long-term client contracts and manufacturing scale can stabilize cash flows and help absorb fixed costs across product cycles.
Bears Say
Sharp Revenue DeclineA steep trailing‑twelve‑month revenue drop erodes scale economics and undermines fixed-cost absorption. Persisting top-line weakness can force margin cuts, reduce bargaining leverage with suppliers, and impair long-term investment in product development or customer-retention initiatives.
Low Gross MarginA structurally low gross margin provides a thin buffer against rising input or labor costs and limits funds available for marketing or R&D. Over time this compresses operating leverage, makes profitability sensitive to volume swings, and constrains the firm's ability to improve returns on invested capital.
Profitability Volatility And Return To Net LossReversion to a net loss highlights earnings instability. Persistent volatility undermines retained-earnings growth, could limit reinvestment capacity, and raises the likelihood of cost-cutting or capital raises that may harm long-term growth initiatives and stakeholder confidence.
Integrated BioPharma News
INBP FAQ
What was Integrated BioPharma Inc’s price range in the past 12 months?
Integrated BioPharma Inc lowest stock price was $0.25 and its highest was $0.42 in the past 12 months.
What is Integrated BioPharma Inc’s market cap?
Integrated BioPharma Inc’s market cap is $8.67M.
When is Integrated BioPharma Inc’s upcoming earnings report date?
Integrated BioPharma Inc’s upcoming earnings report date is May 07, 2026 which is in 32 days.
How were Integrated BioPharma Inc’s earnings last quarter?
Integrated BioPharma Inc released its earnings results on Feb 11, 2026. The company reported -$0.024 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.024.
Is Integrated BioPharma Inc overvalued?
According to Wall Street analysts Integrated BioPharma Inc’s price is currently Overvalued.
Does Integrated BioPharma Inc pay dividends?
Integrated BioPharma Inc does not currently pay dividends.
What is Integrated BioPharma Inc’s EPS estimate?
Integrated BioPharma Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Integrated BioPharma Inc have?
Integrated BioPharma Inc has 31,059,610 shares outstanding.
What happened to Integrated BioPharma Inc’s price movement after its last earnings report?
Integrated BioPharma Inc reported an EPS of -$0.024 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3%.
Which hedge fund is a major shareholder of Integrated BioPharma Inc?
Currently, no hedge funds are holding shares in INBP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Integrated BioPharma Inc
Integrated BioPharma, Inc., together with its subsidiaries, manufactures, distributes, markets, and sells vitamins, nutritional supplements, and herbal products primarily in the United States, Luxembourg, and Canada. It operates through Contract Manufacturing and Other Nutraceutical Businesses segments. The Contract Manufacturing segment manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers, and specialized healthcare providers. The Other Nutraceutical Businesses segment distributes healthful nutritional products for sale through mass market, grocery, drug, and vitamin retailers under the Peaceful Sleep and Wheatgrass brands, as well as other branded proprietary nutraceutical products. This segment also sells private label vitamin and nutritional supplement products through the Internet; provides warehousing and fulfilment services; and distributes fine natural botanicals, including multi minerals, as well as raw materials. The company was formerly known as Integrated Health Technologies, Inc. Integrated BioPharma, Inc. was incorporated in 1980 and is based in Hillside, New Jersey.
Technical Analysis
Natural Alternatives International
―
Sow Good
―
FitLife Brands
―
Bon Natural Life
―
Healthy Choice Wellness Corp. Class A
―
Ownership Overview
Options Prices
Currently, No data available
---